- Home
- CCBG vs PHAT Comparison
CCBG vs PHAT Comparison
Compare CCBG & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCBG
- PHAT
- Stock Information
- Founded
- CCBG 1895
- PHAT 2018
- Country
- CCBG United States
- PHAT United States
- Employees
- CCBG N/A
- PHAT N/A
- Industry
- CCBG Major Banks
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- CCBG Finance
- PHAT Health Care
- Exchange
- CCBG Nasdaq
- PHAT Nasdaq
- Market Cap
- CCBG 647.6M
- PHAT 727.5M
- IPO Year
- CCBG N/A
- PHAT 2019
- Fundamental
- Price
- CCBG $41.34
- PHAT $8.91
- Analyst Decision
- CCBG Buy
- PHAT Strong Buy
- Analyst Count
- CCBG 2
- PHAT 5
- Target Price
- CCBG $39.00
- PHAT $16.40
- AVG Volume (30 Days)
- CCBG 38.4K
- PHAT 5.0M
- Earning Date
- CCBG 07-22-2025
- PHAT 08-07-2025
- Dividend Yield
- CCBG 2.32%
- PHAT N/A
- EPS Growth
- CCBG 11.98
- PHAT N/A
- EPS
- CCBG 3.37
- PHAT N/A
- Revenue
- CCBG $236,037,000.00
- PHAT $81,859,000.00
- Revenue This Year
- CCBG $10.45
- PHAT $195.45
- Revenue Next Year
- CCBG $3.50
- PHAT $106.76
- P/E Ratio
- CCBG $12.26
- PHAT N/A
- Revenue Growth
- CCBG 6.63
- PHAT 3055.70
- 52 Week Low
- CCBG $26.72
- PHAT $2.21
- 52 Week High
- CCBG $41.54
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- CCBG 71.97
- PHAT 53.97
- Support Level
- CCBG $37.87
- PHAT $8.72
- Resistance Level
- CCBG $41.00
- PHAT $10.13
- Average True Range (ATR)
- CCBG 0.98
- PHAT 0.81
- MACD
- CCBG 0.37
- PHAT -0.33
- Stochastic Oscillator
- CCBG 100.00
- PHAT 3.96
About CCBG Capital City Bank Group
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company operates in one segment with two principal services: Banking Services and Wealth Management Services. It offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services among others through its banking offices in Florida, Georgia, and Alabama.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.